Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2

American Journal of Pathology

Volumn 161, Issue 6, 2002, Pages 2053-2063

  Cao, Yue ^a   Lundwall, Åke ^a   Gadaleanu, Virgil ^a   Lilja, Hans ^a   Bjartell, Anders ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; HEPARIN; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; TISSUE KALLIKREIN; TISSUE KALLIKREIN 2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN FAMILY; STROMA CELL; TISSUE HOMOGENATE; WESTERN BLOTTING;

EID: 0036898045     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64484-7     Document Type: Article

References (52)

1. Bjork I, Olson ST: Anti-thrombin. A bloody important serpin. Adv Exp Med Biol 1997, 425:17-33
2. Skinner R, Abrahams JP, Whisstock JC, Lesk AM, Carrell RW, Wardell MR: The 2.6 A structure of anti-thrombin indicates a conformational change at the heparin binding site. J Mol Biol 1997, 266:601-609
3. Olson ST, Bjork I, Sheffer R, Craig PA, Shore JD, Choay J: Role of the anti-thrombin-binding pentasaccharide in heparin acceleration of anti-thrombin-proteinase reactions. Resolution of the anti-thrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992, 267:12528-12538
4. Lahiri B, Bagdasarian A, Mitchell B, Talamo RC, Colman RW: Antithrombin-heparin cofactor: An inhibitor of plasma kallikrein. Arch Biochem Biophys 1976, 175:737-747
5. Bjork I, Nordling K, Larsson I, Olson ST: Kinetic characterization of the substrate reaction between a complex of anti-thrombin with a synthetic reactive-bond loop tetradecapeptide and four target proteinases of the inhibitor. J Biol Chem 1992, 267:19047-19050
6. Danielsson A, Bjork I: Mechanism of inactivation of trypsin by antithrombin. Biochem J 1982, 207:21-28
7. Nordenman B, Nystrom C, Bjork I: The size and shape of human and bovine anti-thrombin II. Eur J Biochem 1977, 78:195-203
8. Edmunds T, Van Patten SM, Pollock J, Hanson E, Bernasconi R, Higgins E, Manavalan P, Ziomek C, Meade H, McPherson JM, Cole ES: Transgenically produced human anti-thrombin: Structural and functional comparison to human plasma-derived anti-thrombin. Blood 1998, 91:4561-4571
9. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J: Anti-angiogenic activity of the cleaved conformation of the serpin anti-thrombin. Science 1999, 285:1926-1928
10. Larsson H, Sjoblom T, Dixelius J, Ostman A, Ylinenjarvi K, Bjork I, Claesson-Welsh L: Anti-angiogenic effects of latent anti-thrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Res 2000, 60:6723-6729
11. Larsson H, Akerud P, Nordling K, Raub-Segall E, Claesson-Welsh L, Bjork I: A novel anti-angiogenic form of anti-thrombin with retained proteinase binding ability and heparin affinity. J Biol Chem 2001, 276:11996-12002
12. Akiyama K, Nakamura K, Makino I, Takeda Y, Kubota K, Tazawa S, Hayashi T, Niiya K, Sakuragawa N: Anti-thrombin III producing hepatocellular carcinoma. Thromb Res 1993, 72:193-201
13. Zacharski LR, Memoli VA, Rousseau SM, Kisiel W: Ocurrence of blood coagulation factors in situ in small cell carcinoma of the lung. Cancer 1987, 60:2675-2681
14. Zacharski LR: Small cell carcinoma of the lung: Interaction with the blood coagulation mechanism and treatment with anticoagulants. Onkologie 1987, 10:264-270
15. Kisker O, Onizuka S, Banyard J, Komiyama T, Becker CM, Achilles EG, Barnes CM, O'Reilly MS, Folkman J, Pirie-Shepherd SR: Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res 2001, 61:7298-7304
16. Bick RL: Anti-thrombin III and factor VIII in patients with neoplasms. Am J Clin Pathol 1978, 69:194-195
17. Honegger H, Anderson N, Hewitt LA, Tullis JL: Anti-thrombin III profiles in malignancy, relationship primary tumors and metastatic site. Thromb Haemost 1981, 46:500-503
18. Blomback M, Edsmyr F, Kockum C, Paul C: Blood coagulation studies in patients with advanced carcinoma of the prostate treated with 2,6-cis-diphenylhexamethylcyclotetra-siloxane or estramustine-17-phosphate Urol Res 1978, 6:95-102
19. Buller HR, Boon TA, Henny CP, Dabhoiwala NF, ten Cate JW: Estrogen-induced deficiency and decrease in anti-thrombin III activity in patients with prostatic cancer. J Urol 1982, 128:72-74
20. Hayashi T, Takenawa J, Ryoji O, Hiura M, Taki Y, Kiriyama T: Effect of estrogen treatment on anti-thrombin III activity in patients with carcinoma of the prostate Hinyokika Kiyo 1989, 35:807-813
21. Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy GP, Chu TM: Prostate antigen: A new potential marker for prostatic cancer. Prostate 1981, 2:89-96
22. Killian CS, Enrich LJ, Vargas FP, Kuriyama M, Wang MC, Slack NH, Papsidero LD, Murphy GP, Chu TM: Investigators of the National Prostatic cancer Project: Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer. Cancer Res 1985, 45:886-891
23. Bourgeois L, Brillard-Bourdet M, Deperthes D, Juliano MA, Juliano L, Tremblay RR, Dube JY, Gauthier F: Serpin-derived peptide substrates for investigating the substrate specificity of human tissue kallikreins hK1 and hK2. J Biol Chem 1997, 272:29590-29595
24. Schedlich LJ, Bennetts BH, Morris BJ: Primary structure of a human glandular kallikrein gene. DNA 1987, 6:429-437
25. Akiyama K, Nakamura T, Iwanaga S, Hara M: The chymotrypsin-like activity of human prostate-specific antigen, gamma-seminoprotein. FEBS Lett 1987, 225:168-172
26. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991, 51:222-226
27. Lilja H: Role of hK2, free PSA, and complexed PSA measurements in the very early detection of prostate cancer. Eur Urol 2001, 39:47-48
28. Christensson A, Bjork T, Nilsson O, Dahlen U, Matikainen MT, Cockett AT, Abrahamsson PA, Lilja H: Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993, 150:100-105
29. Mikolajczyk SD, Millar LS, Kumar A, Saedi MS: Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors. Prostate 1998, 34:44-50
30. Deperthes D, Chapdelaine P, Tremblay RR, Brunet C, Berton J, Hebert J, Lazure C, Dube JY: Isolation of prostatic kallikrein hK2, also known as hGK-1, in human seminal plasma. Biochim Biophys Acta 1995, 1245:311-316
31. Frenette G, Deperthes D, Tremblay RR, Lazure C, Dube JY: Purification of enzymatically active kallikrein hK2 from human seminal plasma. Biochim Biophys Acta 1997, 1334:109-115
32. Mikolajczyk SD, Millar LS, Kumar A, Saedi MS: Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1. Int J Cancer 1999, 81:438-442
33. Diamandis EP, Yousef GM, Luo LY, Magklara A, Obiezu CV: The new human kallikrein gene family: Implications in carcinogenesis. Trends Endocrinol Metab 2000, 11:54-60
34. Fortier AH, Nelson BJ, Grella DK, Holaday JW: Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst 1999, 91:1635-1640
35. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, Lovgren T: Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991, 37:1618-1625
36. McKay EJ: A simple two-step procedure for the isolation of antithrombin III from biological fluids. Thromb Res 1981, 21:375-382
37. Christensson A, Laurell CB, Lilja H: Enzymatic activity of prostatespecific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990, 194:755-763
38. Lovgren J, Rajakoski K, Karp M, Lundwall A, Lilja H: Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 1997, 238:549-555
39. Lovgren J, Tian S, Lundwall A, Karp M, Lilja H: Production and activation of recombinant hK2 with propeptide mutations resulting in high expression levels. Eur J Biochem 1999, 266:1050-1055
40. Bock SC, Harris JF, Balazs I, Trent JM: Assignment of the human anti-thrombin III structural gene to chromosome 1q23-25. Cytogenet Cell Genet 1985, 39:67-69
41. Bjartell A, Bjork T, Matikainen MT, Abrahamsson PA, di Sant'Agnese A, Lilja H: Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium. Urology 1993, 42:502-510
42. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ: Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic Acids Res 1997, 25: 3389-3402
43. Bjartell A, Malm J, Moller C, Gunnarsson M, Lundwall A, Lilja H: Distribution and tissue expression of Semenogelin I and II in man as demonstrated by in situ hybridization and immunocytochemistry. J Androl 1996, 17:17-26
44. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KA, Stein H, Mason DY: Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984, 32:219-229
45. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685
46. Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR: Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999, 54:523-527
47. Hahn D, Simak R, Steiner GE, Handisurya A, Susani M, Marberger M: Expression of the VEGF-receptor Fit-1 in benign, premalignant and malignant prostate tissues. J Urol 2000, 164:506-510
48. Ravindranath N, Wion D, Brachet P, Djakiew D: Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 2001, 22:432-443
49. Latil A, Lidereau R: Genetic aspects of prostate cancer. Virchows Arch 1998, 432:389-406
50. Elo JP, Visakorpi T: Molecular genetics of prostate cancer. Ann Med 2001, 33:130-141
51. Bjork T, Bjartell A, Abrahamsson PA, Hulkko S, di Sant'Agnese A, Lilja H: Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 1994, 43:427-434
52. Paju A, Bjartell A, Zhang WM, Nordling S, Borgstrom A, Hansson J, Stenman UH: Expression and characterization of trypsinogen produced in the human male genital tract. Am J Pathol 2000, 157:2011-2021